ArticleApplied biochemistry and biotechnology2026
Selective Anticancer Effects of Portulaca grandiflora via Apoptosis and NF-κB Pathway Modulation in MDA-MB-231 Cells.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains the most prevalent malignancy worldwide, with triple-negative breast cancer (TNBC) being particularly aggressive and resistant to standard therapies. Plant-derived compounds have emerged as promising alternatives due to selective cytotoxicity and reduced adverse effects. Portulaca grandiflora (Portulacaceae), ornamental succulent rich in flavonoids, phenolics, carotenoids, and sterols-phytochemicals commonly associated with anticancer activity-was evaluated for its pro-apoptotic and anti-metastatic potential. Three crude extracts, methanolic (PGM), ethanolic (PGE), and n-hexane (PGH), were initially screened for cytotoxicity, after which the two most active extracts, PGM and PGH, were selected for detailed mechanistic analysis. MTT assay was used for antiproliferative screening against MDA-MB-231 TNBC cells and non-tumorigenic MCF-10 A breast epithelial cells. Apoptosis induction was assessed using sub-G1 cell cycle arrest, Annexin V/PI staining, DNA fragmentation, and caspase-3/7 activation assays. NF-κB signaling and associated survival proteins were evaluated through Western blot, luciferase reporter, and DNA-binding assays. Anti-migratory and anti-invasive effects were analyzed using wound healing and transwell invasion assays. PGM showed the lowest IC₅₀ (79.5 µg/mL at 72 h) with minimal toxicity to MCF-10 A cells. Both PGM and PGH triggered sub-G1 accumulation and dose-dependent apoptosis, with PGM eliciting stronger caspase-3/7 activation, DNA fragmentation, and PARP cleavage. Notably, PGM inhibited NF-κB DNA-binding activity by ~ 60% compared to ~ 40% with PGH, reduced IκBα, TAK1, and Akt phosphorylation, and prevented nuclear p65 translocation, accompanied by downregulation of Bcl-2, Bcl-xL, XIAP, survivin, and Cyclin D1. Migration and invasion were significantly suppressed (p < 0.01), confirming anti-metastatic efficacy. Collectively, these findings demonstrate that P. grandiflora extracts-especially PGM-selectively induce apoptosis and impede metastasis in TNBC cells through suppression of NF-κB signaling activity (association-based evidence), supporting its potential as a phytochemical source for targeted breast cancer therapy. Because pathway-causality was not tested using NF-κB rescue or pharmacological inhibition controls, the mechanistic conclusions are presented as supportive associations rather than definitive proof. Future studies should focus on bioassay-guided compound purification, synergistic combination assessment, and in vivo validation for translational advancement.
Indexed as
Identifiers
42262678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.